Regulatory Daily Summary
Regulatory Daily Summary: What Happened on November 11, 2026
FDA clears Sunharbo for stroke prevention and adds a possible GLP-1 eye-risk warning
The FDA also approved Pimjetmi for a rare joint tumor. Tandem recalled its Mobi insulin pump, and the UK approved a new anal cancer treatment.
Today in brief
Bayer’s Sunharbo won FDA approval to prevent another stroke, while GLP-1 drugmakers must add a warning about a possible rare eye risk.12 The FDA approved Merck KGaA’s Pimjetmi for some adults with tenosynovial giant cell tumor, and Tandem recalled its Mobi insulin pump after reporting 230 associated adverse events.34
The UK authorized retifanlimab with chemotherapy for advanced anal cancer on November 5.5
Sunharbo becomes the first approved Factor XIa inhibitor
The FDA approved Bayer’s 50-mg Sunharbo, or asundexian, with antiplatelet therapy for adults with a recent non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.16 It is the first Factor XIa inhibitor approved worldwide, according to approval coverage.1
In the Phase 3 OCEANIC-stroke trial, adding asundexian reduced ischemic stroke by 26% versus antiplatelet therapy alone, while major bleeding rates were similar to placebo.16 Bayer said the once-daily pill would launch in mid-November.7 China has also approved the drug, while applications in other markets remain under review.1
FDA adds a possible rare eye risk to GLP-1 labels
The FDA directed manufacturers of approved GLP-1 receptor agonists to warn about a possible increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause vision loss.2 The agency said patients and caregivers should contact a health professional promptly if symptoms arise. People with a previous NAION event should discuss whether to continue treatment with their clinician.2
The FDA said its review included clinical trials, observational studies, animal data, postmarketing reports and case reports.2 A meta-analysis of 126 trials covering 134,253 patients identified 15 probable cases: 10 among GLP-1 users and five among placebo recipients.2 Estimated incidence was 6.4 cases per 100,000 person-years among GLP-1 users and 3.8 among comparator-treated patients.2
A retrospective study found no statistically significant increase in NAION risk with GLP-1 drugs versus SGLT-2 inhibitors, but found an increased risk versus DPP-4 inhibitors.2 The FDA said the combined evidence points to a possible increased risk of these rare events.2
Pimjetmi approved for adults with symptomatic joint tumors when surgery may cause harm
The FDA approved Merck KGaA’s once-daily oral drug Pimjetmi, or pimicotinib, for adults with symptomatic tenosynovial giant cell tumor when surgery could worsen functional limits or cause severe complications.389 The tumor grows around joints and can affect pain, mobility and physical function.3
In the Phase 3 Maneuver trial, 56% of patients taking pimicotinib had an objective tumor response at week 25, compared with 3% on placebo.38 The trial also found improved range of motion, physical function and pain compared with placebo.9
Merck reported no evidence of cholestatic liver toxicity in the trial. Adverse events led one patient to stop treatment and five to reduce their dose.39 Other approved drugs for the disease have liver-related label precautions, including a boxed warning for Turalio.9
Tandem recalls Mobi insulin pump after 230 adverse events
Tandem recalled its Mobi insulin pump after reporting 230 associated adverse events.4 An FDA recall-database entry says a false occlusion alarm could interrupt insulin delivery.4
UK approves retifanlimab with chemotherapy for advanced anal cancer
The MHRA approved retifanlimab, marketed as Zynyz, for adults with anal canal squamous cell carcinoma that cannot be removed surgically and is metastatic or has returned locally.5 The agency granted the authorization to Incyte Biosciences UK through its International Recognition Procedure on November 5.5
Patients receive the treatment by infusion every four weeks with carboplatin and paclitaxel during the first six cycles.5 In a study of 308 people, retifanlimab plus chemotherapy extended the time before cancer worsened compared with placebo plus chemotherapy.5 The MHRA had previously authorized retifanlimab for advanced Merkel cell carcinoma and said it will continue monitoring the drug’s safety and effectiveness.5
Also worth knowing
-
F
Two FDA warning letters cited Pro-Optics and Next Medical Products for changing materials in contact lens cases and ultrasound gel without submitting new 510(k) applications.10
-
The FDA had more than 1,000 open positions while recovering from a staff departure that left the agency understaffed, PharmaVoice reported.11
Also published
- STAT+: Most-favored nations policy makes drugmakers rethink launches abroad STAT Biotech
- From recommendation to reality: Why newborn screening needs funding now Bio.News
- Drug price hikes in Germany could push US costs higher, study says BioPharma Dive
- AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning BioPharma Dive
- ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval Applied Clinical Trials
- Merck's rare tumour drug Pimjetmi claims FDA approval pharmaphorum
- Democrat midterm landslide spells greater Trump oversight, marginal reforms Clinical Trials Arena
- From EU HTA Implementation to Strategic Action: Dr Thomas Ecker on the New JCA Executive Forum EUCOPE
- First factor XIa inhibitor nabs FDA approval for stroke prevention Nature Reviews Drug Discovery
- STAT+: GLP-1s are given an FDA warning for rare eye condition risk STAT Biotech
- FDA orders blindness risk warning to GLP-1 agonist labels pharmaphorum
- Bayer bags FDA green light for stroke drug Sunharbo pharmaphorum
- Overton confirmation unlikely, Brenner under consideration as acting FDA commissioner BioCentury
- What the U.S. midterms mean for biopharma — a BioCentury podcast BioCentury